ライフサイエンスコーパス: clindamycin

1 nicillin-allergic patient, which now include clindamycin.

2 s samples, more than 92% were susceptible to clindamycin.

3 nterococcus faecalis and use of linezolid or clindamycin.

4 y similar between groups but tended to favor clindamycin.

5 fter combination treatment with fosmidomycin-clindamycin.

6 sses tested or resistant to erythromycin and clindamycin.

7 of the CA-MRSA isolates were susceptible to clindamycin.

8 th a high proportion of susceptible strains, clindamycin.

9 leads to resistance to erythromycin but not clindamycin.

10 istant, inducibly resistant, or sensitive to clindamycin.

11 ores 2 days after receiving a single dose of clindamycin.

12 None were resistant to clindamycin.

13 cherichia coli where it is predicted to bind clindamycin.

14 trong selective advantage in the presence of clindamycin.

15 sion was minimally affected by subinhibitory clindamycin.

16 ions, atovaquone + azithromycin or quinine + clindamycin.

17 d the same concentrations of pneumococci and clindamycin.

18 cin-resistant strains were also resistant to clindamycin.

19 of the nonepidemic strains were resistant to clindamycin.

20 h outbreak were tested for susceptibility to clindamycin.

21 ile and was associated with increased use of clindamycin.

22 ere constitutively or inducibly resistant to clindamycin.

23 resistance to tetracycline, erythromycin and clindamycin.

24 old use of macrolides, fluoroquinolones, and clindamycin.

25 the resistance of streptococcal biofilms to clindamycin.

26 icrog/ml), amphotericin B (2 microg/ml), and clindamycin (1 microg/ml).

27 om each of the three water matrixes revealed clindamycin (1.1 microg/L) in surface water and multiple

28 (80.8% resistant or intermediate resistant), clindamycin (100% resistant to 2 mug/mL), and metronidaz

29 floxacin (500 mg twice daily for 10 days) or clindamycin (150 mg 4 times daily for 10 days) on the fe

30 cs and the ribosome inhibitors thiostrepton, clindamycin-2-phosphate, and puromycin are the first rep

31 Erythromycin (39.5%) and clindamycin (26.4%) resistance was common.

32 imethoprim-sulfamethoxazole (10 strains) and clindamycin (3 strains).

33 uncomplicated wound infection received oral clindamycin 300 mg 4 times daily or TMP-SMX 320 mg/1600

34 en with one of these signs to receive either clindamycin 300 mg or placebo orally twice daily for 5 d

35 Adverse events were more frequent with clindamycin (58 of 265 [21.9%]) than with TMP-SMX (29 of

36 RSA isolates, 95 percent were susceptible to clindamycin, 6 percent to erythromycin, 60 percent to fl

37 thereafter) for seven days (40 subjects) or clindamycin (600 mg every 8 hours) and quinine (650 mg e

38 lower concordance for erythromycin (73.9%), clindamycin (65.5%), and trimethoprim-sulfamethoxazole (

39 follows: oxacillin, 82%; erythromycin, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfam

40 antibiotics except erythromycin (92.1%) and clindamycin (89.5%).

41 0% of the strains tested were susceptible to clindamycin, 96% were susceptible to penicillin and ceft

42 for enterotoxin D (74.5%); and resistant to clindamycin (98.6%), erythromycin (99.0%), and levofloxa

43 Clindamycin alone was less effective than penicillin/IVI

44 Clindamycin also reduced adverse outcomes across the ran

45 Use of all antimicrobial agents except clindamycin and amikacin was significantly reduced.

46 d in an unknown sample and susceptibility to clindamycin and cefoxitin can be ascertained.

47 aureus) and determine its susceptibility to clindamycin and cefoxitin.

48 rains of each species were also resistant to clindamycin and erythromycin and carried the erm(A) (S.

49 -MRSA and HA-MRSA isolates were resistant to clindamycin and erythromycin, but CA-MRSA was more susce

50 these were also constitutively resistant to clindamycin and had the erm(B) gene.

51 Inhibition of nuclease activity by clindamycin and immunoglobulin enhanced S. aureus cleara

52 Emerging treatments for strep TSS include clindamycin and intravenous gamma-globulin.

53 The use of clindamycin and intravenous immunoglobulin (IVIG) in tre

54 r differences in the susceptibility rates to clindamycin and levofloxacin according to patient age gr

55 In contrast, susceptibility rates to clindamycin and levofloxacin varied from 94.0% and 60.7%

56 ed >/= 65 years, whereas resistance rates to clindamycin and levofloxacin were lowest among isolates

57 In contrast, clindamycin and linezolid markedly suppressed translatio

58 anslation inhibitors (such as tetracyclines, clindamycin and macrolides) and gyrase inhibitors (such

59 ator-associated pneumonia (VAP) who received clindamycin and piperacillin-tazobactam as part of their

60 mpared with 72 percent of those who received clindamycin and quinine (P<0.001).

61 romycin and 73 percent of those who received clindamycin and quinine (P=0.66), and after six months n

62 azithromycin is as effective as a regimen of clindamycin and quinine and is associated with fewer adv

63 unosuppressive therapy and administration of clindamycin and quinine antimicrobials.

64 A course of clindamycin and quinine is the standard treatment, but t

65 Although treatment with clindamycin and quinine reduces the duration of parasite

66 sh (each in 8 percent of the subjects); with clindamycin and quinine the most common adverse effects

67 days in 22 acutely ill subjects who received clindamycin and quinine therapy (P=0.03), of whom 9 had

68 Antibiotic treatment with combinations of clindamycin and rifampicin, or ertapenem followed by com

69 The association between clindamycin and shorter duration of colonization after M

70 nce of the CC5 clone in 2010 with associated clindamycin and tetracycline resistance.

71 and 13.0% of the isolates were resistant to clindamycin and tetracycline, respectively.

72 wo days later, they were given injections of clindamycin and then challenged 1 day later with differe

73 In settings where MRSA is prevalent, clindamycin and TMP-SMX produce similar cure and adverse

74 We found no significant difference between clindamycin and TMP-SMX, with respect to either efficacy

75 Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX)

76 nd 62% and 36% of isolates were resistant to clindamycin and trimethoprim/sulfamethoxazole, respectiv

77 Clindamycin and vasopressor intensity were higher among

78 4% were susceptible to doxycycline, 29.7% to clindamycin, and 21.6% to trimethoprim-sulfamethoxazole.

79 the ketolide telithromycin, the lincosamide clindamycin, and a phenicol, chloramphenicol, at resolut

80 ribosome-targeting antibiotics: tobramycin, clindamycin, and chloramphenicol.

81 more likely to be sensitive to erythromycin, clindamycin, and ciprofloxacin.

82 es that were susceptible to chloramphenicol, clindamycin, and erythromycin were lower in 2003 and 200

83 so-called 4C (cephalosporins, co-amoxiclav, clindamycin, and fluoroquinolones) and macrolide antibio

84 igh MICs for erythromycin, azithromycin, and clindamycin, and intermediate to high MICs for moxifloxa

85 Penicillin, clindamycin, and intravenous immune globulin (Venoglobul

86 n general, resistance rates to erythromycin, clindamycin, and levofloxacin were higher in the populat

87 Tetracycline, erythromycin, clindamycin, and metronidazole revealed poor in vitro ac

88 ing intravenous ciprofloxacin, rifampin, and clindamycin, and supportive therapy appears to have slow

89 xacin, norfloxacin, aztreonam, erythromycin, clindamycin, and trimethoprim-sulfamethoxazole.

90 ed with significantly more fluoroquinolones, clindamycin, and vancomycin (P < .0001) for each antibio

91 s (1 mug/ml + 0.25 mug/ml [erythromycin plus clindamycin] and 1 mug/ml + 0.5 mug/ml) with three diffe

92 rolonged to the same degree as with 25 mg/kg clindamycin, another widely used drug against toxoplasmo

93 Our model recapitulates known dynamics of clindamycin antibiotic treatment and C. difficile infect

94 s in the context of a critical health issue: clindamycin antibiotic treatment and opportunistic Clost

95 and azithromycin) and lincosamide (including clindamycin) antibiotics are recommended for treatment o

96 quinine plus tetracycline or doxycycline or clindamycin are the best treatment options.

97 for susceptibility to amoxicillin at 8 mg/L, clindamycin at 4 mg/L, doxycycline at 4 mg/L, and metron

98 esistance of S. pyogenes to erythromycin and clindamycin at an urban tertiary-care hospital.

99 ponsible; remarkably, however, subinhibitory clindamycin blocked production of several of the individ

100 the respiratory tract for susceptibility to clindamycin by agar disk diffusion is an easy and inexpe

101 Resistance to clindamycin by bacterial vaginosis-associated anaerobic

102 four combinations of erythromycin (ERY) and clindamycin (CC) (ERY and CC at 4 and 0.5, 6 and 1, 8 an

103 lity testing with amoxicillin, azithromycin, clindamycin, ciprofloxacin, and doxycycline on blood-sup

104 g treatment for four of the six antibiotics (clindamycin, ciprofloxacin, penicillin-G, and trimethopr

105 oth microdilution (BMD) were used to perform clindamycin (CLI) induction testing on 128 selected nond

106 Addition of clindamycin (CLI) is recommended, although clinical evid

107 fepime, cefotaxime (CTX), ceftriaxone (CTR), clindamycin (CLI), erythromycin (ERY), gatifloxacin, lev

108 xigenic C. difficile after administration of clindamycin (Cm).

109 the use of 4C antibiotics (fluoroquinolones, clindamycin, co-amoxiclav, and cephalosporins) and other

110 The sensitivity of the erythromycin plus clindamycin combination of 1 mug/ml + 0.25 mug/ml was 91

111 synergy with Clarithromycin, Doxycycline and Clindamycin, combinations of which were taken forward fo

112 reater numbers under selective pressure from clindamycin, compared with a control strain.

113 tudy assessed two different erythromycin and clindamycin concentration combinations in single wells (

114 ion test (D-zone test) with erythromycin and clindamycin disks and a single-well broth test combining

115 Simple placement of erythromycin and clindamycin disks at a distance achieved with a standard

116 and children to evaluate whether 2-microgram clindamycin disks can distinguish between isolates manif

117 the reliability of placing erythromycin and clindamycin disks in adjacent positions (26 to 28 mm apa

118 tilize closely approximated erythromycin and clindamycin disks; the flattening of the clindamycin zon

119 inal flora and bacterial vaginosis with oral clindamycin early in the second trimester significantly

120 y testing revealed over 100-fold increase of clindamycin EC(50) in strains harboring one of these mut

121 sk diffusion D-zone test and an erythromycin-clindamycin (ERY + CLI) single-well broth test for induc

122 This study assessed an erythromycin-clindamycin (ERY-CC) broth test for inducible CC resista

123 greater resistance than SCCmec-IV strains to clindamycin, erythromycin, levofloxacin, gentamicin, rif

124 mycin-resistant isolates were susceptible to clindamycin even upon induction with erythromycin and ha

125 and primary-case use of fluoroquinolones and clindamycin exceeding total use thresholds.

126 ach strain, 10 hamsters were given 1 dose of clindamycin, followed 5 days later with 100 C. difficile

127 10 hamsters per strain were given 1 dose of clindamycin, followed 5 days later with gastric inoculat

128 ycin monotherapy vs combination therapy with clindamycin for ABSSSIs.

129 e-well broth test combining erythromycin and clindamycin for detection of inducible clindamycin resis

130 recommends prompt diagnosis and quinine plus clindamycin for treatment of uncomplicated malaria in th

131 n the variability of inducible resistance to clindamycin found in our two hospitals, we conclude that

132 Resistance to clindamycin further increases the risk of C. difficile-a

133 MSSA became more resistant to ciprofloxacin, clindamycin, gentamicin sulfate, and trimethoprim-sulfam

134 ased antibiotic resistance to ciprofloxacin, clindamycin, gentamicin, and trimethoprim-sulfamethoxazo

135 1 month of follow-up were less common in the clindamycin group (15 of 221, 6.8%) than in the TMP-SMX

136 al of 524 patients were enrolled (264 in the clindamycin group and 260 in the TMP-SMX group), includi

137 intention-to-treat population (80.3% in the clindamycin group and 77.7% in the TMP-SMX group; differ

138 uld be evaluated (466 patients; 89.5% in the clindamycin group and 88.2% in the TMP-SMX group; differ

139 The clindamycin group had a significantly lower rate of recu

140 ion, the cure rate among participants in the clindamycin group was similar to that in the TMP-SMX gro

141 Exposure to ciprofloxacin or clindamycin had a strong effect on the diversity of the

142 Women receiving clindamycin had significantly fewer miscarriages or pret

143 the pyrosequencing results, it appears that clindamycin has more impact than ciprofloxacin on the in

144 nolone plus amoxicillin/clavulanate (or plus clindamycin if penicillin allergic) is recommended as em

145 n the adult samples, 50% were susceptible to clindamycin in 2003 and 2004, whereas greater than 75% w

146 dilution test incorporating erythromycin and clindamycin in combination is a sensitive and specific i

147 This mutant was highly resistant to clindamycin in in vitro translation reactions and yet wa

148 ccus hominis isolate, six VMEs for inducible clindamycin in S. aureus isolates, and two major errors

149 hat apicoplast translation is the target for clindamycin in Toxoplasma.

150 doxycycline, amoxicillin, metronidazole, or clindamycin, in 55%, 43.3%, 30.3%, and 26.5% of the pati

151 oli) rendered assembled subunits tolerant to clindamycin inhibition.

152 The use of clindamycin is a specific risk factor for diarrhea due t

153 Hospital formulary restriction of clindamycin is an effective way to decrease the number o

154 n-contaminated surgeries, which suggest that clindamycin is an inadequate prophylactic antibiotic the

155 with vancomycin, tobramycin, meropenem, and clindamycin is described.

156 Clindamycin is increasingly used to treat canine pyoderm

157 e resistance to vaginal anaerobic flora when clindamycin is used as treatment.

158 subset of CA-MRSA could be problematic when clindamycin is used.

159 IG (P=.02), penicillin/clindamycin (P=.009), clindamycin/IVIG (P=.04), or all agents combined (P=.02)

160 in, penicillin/clindamycin, penicillin/IVIG, clindamycin/IVIG, or all agents combined.

161 days) and were equally randomized to vaginal clindamycin, lactobacillus-vaginal probiotic or vaginal

162 inhibitors of prokaryotic translation (e.g. clindamycin, macrolides and tetracyclines).

163 We show that a single dose of clindamycin markedly reduces the diversity of the intest

164 tes of MRSA abscesses with susceptibility to clindamycin may reflect the high prevalence level of CAM

165 n reported with amoxicillin/clavulanic acid, clindamycin, metronidazole, and the combination therapy

166 Erythromycin and clindamycin MICs were related to the presence of ermA, e

167 ll ermB(+) isolates were highly resistant to clindamycin (MICs >256 microgram/ml), whereas all mefE(+

168 ml), ciprofloxacin (MICs, <or= 1 microg/ml), clindamycin (MICs, <or=0.5 microg/ml), rifampin (MICs, <

169 mic-strain isolates were highly resistant to clindamycin (minimal inhibitory concentration, >256 micr

170 However, 55% of the isolates had MICs to clindamycin of >0.25 mug/ml, 44% had MICs to erythromyci

171 ceptibilities to penicillin, macrolides, and clindamycin of 1,655 invasive isolates of Streptococcus

172 responsible for the effects of subinhibitory clindamycin on the overall exoprotein pattern.

173 mpicillin or the protein synthesis inhibitor clindamycin or azithromycin.

174 tected in samples containing the antibiotics clindamycin or cefoxitin, the sample is deemed to be res

175 antagonism was observed with the addition of clindamycin or IVIG to penicillin.

176 f BV were randomized to receive intravaginal clindamycin or metronidazole.

177 hat had received treatment with subcutaneous clindamycin or saline.

178 s compared with incision and drainage alone, clindamycin or TMP-SMX in conjunction with incision and

179 ly assigned in a 1:1 ratio to receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) f

180 n high numbers under selective pressure from clindamycin or vancomycin, compared with control strains

181 y Score II (odds ratio [OR], 1.1; P = .007), clindamycin (OR, 8.6; P = .007), and IVIG (OR, 5.6; P =

182 fotetan (P = 0.006), cephalothin (P<0.0001), clindamycin (P = 0.04), erythromycin (P<0.0001), methici

183 ive than penicillin/IVIG (P=.02), penicillin/clindamycin (P=.009), clindamycin/IVIG (P=.04), or all a

184 nonsusceptible to penicillin, erythromycin, clindamycin, penicillin plus erythromycin, and multiple

185 lts of treatment with penicillin, penicillin/clindamycin, penicillin/IVIG, clindamycin/IVIG, or all a

186 Subcutaneous vancomycin, clindamycin, piperacillin-tazobactam, ticarcillin-clavul

187 reated patients (0.31; 95% CI, .09-1.12) and clindamycin plus IVIG-treated patients (0.12; 95% CI, .0

188 tiple case reports, a 7- to 10-day course of clindamycin plus quinine is often used to treat severe b

189 Clindamycin predisposes patients to C. difficile colitis

190 ACT, which were given for 3 days, or quinine-clindamycin (QnC), which was given for 5-7 days, followi

191 prevalence of MLSBi among CA-MRSA isolates, clindamycin remains a useful option for outpatient thera

192 High prevalence of clindamycin resistance (96.2%) was unexpected.

193 us (MRSA) (n = 58), S. aureus with inducible clindamycin resistance (ICR) (n = 30), trimethoprim-sulf

194 ana were performing the D test for inducible clindamycin resistance according to guidelines recommend

195 ensitive and specific indicator of inducible clindamycin resistance and could be included in routine

196 This lineage was commonly associated with clindamycin resistance and, less frequently, tetracyclin

197 The incidences of inducible clindamycin resistance at two hospitals (an inner-city h

198 broth microdilution, examined for inducible clindamycin resistance by D-test, and screened for heter

199 rmedius isolates were positive for inducible clindamycin resistance by double-disk diffusion testing

200 on tests were performed to examine inducible clindamycin resistance by erythromycin induction on both

201 ution method, they were tested for inducible clindamycin resistance by the D-test, and they were scre

202 Constitutive or inducible clindamycin resistance can occur in beta-hemolytic strep

203 hat are close to known mutations that confer clindamycin resistance in other species, but which were

204 This study has shown that inducible clindamycin resistance in staphylococci can be detected

205 n and clindamycin for detection of inducible clindamycin resistance in staphylococci, but only a disk

206 ntrol strains for the detection of inducible clindamycin resistance in staphylococci.

207 3%) were resistant to metronidazole, whereas clindamycin resistance increased significantly for P. bi

208 duced peptidyl transferase activity, whereas clindamycin resistance mutation A2084G (A2058G in E. col

209 oimidazole resistance plasmid pIP417 and the clindamycin resistance plasmid pBFTM10, that is, two mob

210 hromycin resistance rate and a 60% inducible clindamycin resistance rate but were highly susceptible

211 staphylococci (30.6 to 94.1%) with inducible clindamycin resistance rates of 26.0% and 55.0% for oxac

212 4%) were resistant to erythromycin, and high clindamycin resistance rates were observed (28.5% consti

213 Clindamycin resistance remained low until 2003-2004, whe

214 Clindamycin resistance was not seen among the erythromyc

215 d ermA or ermC, 57 demonstrated constitutive clindamycin resistance, and 25 demonstrated inducible re

216 lure of clindamycin therapy due to inducible clindamycin resistance.

217 the positive control organism for inducible clindamycin resistance.

218 (ClnR-4 and ClnR-21) with strong and stable clindamycin resistance.

219 ility testing should be tested for inducible clindamycin resistance.

220 l), 12/158 isolates tested were resistant to clindamycin (resistance breakpoint >/= 8 mug/ml), 10/247

221 No isolate was clindamycin resistant.

222 s were erythromycin resistant, and 6.9% were clindamycin resistant.

223 The emergence of clindamycin-resistant anaerobic gram-negative rods follo

224 d diarrhea was caused by a clonal isolate of clindamycin-resistant C. difficile and was associated wi

225 We identified 12 erythromycin- and clindamycin-resistant emm 90 group A streptococcus (GAS)

226 ) to have nasal colonization than those with clindamycin-resistant MRSA infections (71%; P = 0.042).

227 This evidence of clindamycin-resistant parasites in the Amazon suggests t

228 y related, tetracycline-, erythromycin-, and clindamycin-resistant sequence type 459 (ST459) strains

229 (ST)459, a tetracycline-, erythromycin-, and clindamycin-resistant ST first identified in Minnesota,

230 Clindamycin-resistant subpopulations of P. bivia and bla

231 and inducible or constitutive resistance to clindamycin, respectively, whereas expression of the mef

232 % and 15% were resistant to erythromycin and clindamycin, respectively.

233 In this report, we show that subinhibitory clindamycin (SBCL) eliminates production of nearly all e

234 eports, however, we found that subinhibitory clindamycin stimulates synthesis of coagulase and fibron

235 fficile infection at least 10 days following clindamycin, suggesting that resolution of diarrhea and

236 We examined erythromycin and clindamycin susceptibilities with Etest methodology amon

237 cases/month; P < 0.001), and an increase in clindamycin susceptibility among C. difficile isolates (

238 isolates that are erythromycin resistant but clindamycin susceptible by in vitro antimicrobial suscep

239 overed from these patients, 166 (41.1%) were clindamycin susceptible, 190 (47.0%) carried staphylococ

240 methoxazole (TMP-SMX), and all isolates were clindamycin susceptible.

241 tion on both CA and hospital-associated (HA) clindamycin-susceptible and erythromycin-resistant isola

242 Patients with clindamycin-susceptible MRSA infections were less likely

243 rapy even among women colonized initially by clindamycin-susceptible strains.

244 CA-MRSA isolates, that is, isolates that are clindamycin-susceptible, PVL+, ST8, and/or contain SCCme

245 The clindamycin, tetracycline, and mupirocin resistance gene

246 nizing isolates to penicillin, erythromycin, clindamycin, tetracycline, and other antimicrobial agent

247 ents (penicillin, methicillin, erythromycin, clindamycin, tetracycline, ciprofloxacin, vancomycin, tr

248 Individual or multiple resistance to clindamycin, tetracycline, erythromycin, levofloxacin, o

249 978 through 1983), the most common cause was clindamycin, the standard diagnostic test was the cytoto

250 TSS patients demonstrates that both IVIG and clindamycin therapy contribute to a significantly improv

251 We report a case of failure of clindamycin therapy due to inducible clindamycin resista

252 be made in health policy away from quinine + clindamycin therapy for malaria in pregnant women and in

253 ficantly worse (survival rate, 56%) than (1) clindamycin therapy used either alone (82%) or in combin

254 The patient received long-term oral clindamycin therapy, which cured her disseminated infect

255 obic gram-negative rods persisting following clindamycin therapy.

256 spitals to assess the relation of the use of clindamycin to C. difficile-associated diarrhea.

257 addition of the protein synthesis inhibitor clindamycin to S. aureus LAC cultures decreased nuc1 tra

258 dual antimicrobial agents ranged from 90.4% (clindamycin) to 100% (vancomycin and gatifloxacin).

259 was cured at 7-14 days in 187 of 203 (92.1%) clindamycin-treated and 182 of 198 (91.9%) TMP-SMX-treat

260 After orogastric inoculation of VRE, clindamycin-treated mice acquired high concentrations of

261 to high concentrations in cecal contents of clindamycin-treated mice and in cecal mucus of both grou

262 Inoculation of clindamycin-treated mice with C. difficile (VPI 10463) s

263 stimate of the OR for mortality was lower in clindamycin-treated patients (0.31; 95% CI, .09-1.12) an

264 Clindamycin-treated patients had more severe disease tha

265 iota to be normalized after ciprofloxacin or clindamycin treatment differed for various bacterial spe

266 the intestinal microbiota of mice following clindamycin treatment in the presence or absence of C. d

267 Our data suggest that clindamycin treatment of patients with severe iGAS infec

268 ble for recrudescence following fosmidomycin-clindamycin treatment.

269 rticipants were randomly assigned to receive clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or

270 CA-MRSA is usually susceptible to clindamycin, trimethoprim-sulfamethoxazole, and rifampin

271 l MRSA isolates were susceptible in vitro to clindamycin, trimethoprim-sulfamethoxazole, and rifampin

272 reated patients had more severe disease than clindamycin-untreated patients but lower mortality (15%

273 ients (0.12; 95% CI, .01-1.29) compared with clindamycin-untreated patients.

274 romycin-resistant isolates were resistant to clindamycin upon induction with erythromycin and had the

275 ve risk, 2.1 [CI, 1.2 to 3.7]; P = 0.007) or clindamycin use (relative risk, 2.1 [1.2 to 3.6]; P = 0.

276 emic-strain isolates and studied the role of clindamycin use in these outbreaks.

277 roval by an infectious disease consultant of clindamycin use led to an overall reduction in clindamyc

278 indamycin use led to an overall reduction in clindamycin use, a sustained reduction in the mean numbe

279 eas all mefE(+) isolates were susceptible to clindamycin using the 2-microgram disk.

280 vancomycin, amphotericin B, ceftazidime, and clindamycin (VACC) plates.

281 in E. coli) with erythromycin, azithromycin, clindamycin, virginiamycin S, and telithromycin bound ex

282 Combination therapy with vancomycin and clindamycin was associated with decreased hospital LOS f

283 Treatment of the SSTI with clindamycin was associated with earlier clearance (hazar

284 Since frequent use of clindamycin was associated with the outbreak in one of t

285 Screening for resistance to erythromycin and clindamycin was initially accomplished with use of the K

286 of C. difficile that is highly resistant to clindamycin was responsible for large outbreaks of diarr

287 esistance to tetracycline, erythromycin, and clindamycin was seen in 11% (n = 8), 5.8% (n = 20), and

288 el-Haenszel method, we found that the use of clindamycin was significantly increased among patients w

289 Clindamycin was the most active antibiotic against S. co

290 P<0.001), whereas the rate of resistance to clindamycin was the same in the two groups (79 percent).

291 alosporin, aminoglycoside in combination, or clindamycin, was most often selected for empirical thera

292 o antibiotics, particularly erythromycin and clindamycin, was studied.

293 onotherapy or vancomycin in combination with clindamycin were included.

294 atment regimens that contained penicillin or clindamycin were more effective (P<.05) than no treatmen

295 (SC-236) NSAIDs +/- antibiotics (penicillin, clindamycin) were given to mice challenged intramuscular

296 n additional 34 strains showed resistance to clindamycin when exposed to an erythromycin disk in the

297 ylococcus aureus (MRSA) to ciprofloxacin and clindamycin (which has a similar mode of action to macro

298 , 39 demonstrated constitutive resistance to clindamycin, while 33 showed inducible resistance by dis

299 ance were noted for ampicillin-sulbactam and clindamycin, while significant decreases in resistance w

300 and clindamycin disks; the flattening of the clindamycin zone adjacent to the erythromycin disk indic